An Overview of Current Screening and Management Approaches for Prostate Cancer

Author(s): Omar N. Akram, Gohar Mushtaq, Mohammad Amjad Kamal

Journal Name: Current Drug Metabolism

Volume 16 , Issue 8 , 2015

Become EABM
Become Reviewer


Prostate cancer is the fourth leading cause of mortality in Australian men. The prevalence and incidence is increasing in both developed and developing nations, thus there is a need for better screening and management of this disorder. While there is no direct known cause of prostate cancer, management is largely focused on early detection and treatment strategies. Of particular concern is advanced prostate cancer which can manifest as castrate resistant prostate cancer characterized by therapy resistance. This short review outlines the global epidemiology of prostate cancer, clinical manifestations, risk factors, current screening strategies including first line clinical screening as well as the use of circulating biomarkers, and treatment of prostate cancer through mainstream therapeutics as well as the cutting edge peptide and nano-technology based therapeutics that are being implemented or in the process of development to overcome therapeutic obstacles in the treatment of prostate cancer.

Keywords: Castrate resistant prostate cancer, epidemiology, nano-medicine, nano-technology, prostate cancer, prostate specific antigen, therapy resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 07 November, 2015
Page: [713 - 718]
Pages: 6
DOI: 10.2174/1389200216666150812122430
Price: $65

Article Metrics

PDF: 38